ANT-050

N/A

Report date: 2025/01/26 16:13:36

Base Information

Drug NameANT-050
Drug Alias NameVH-VH based bivalent fragment drug conjugate (Antikor Biopharma/Essex Biotechnology)ANT-050
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAntikor Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEssex Bio-Technology LtdAntikor Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A